Treatment of resistant hypertension

Current Hypertension Reports

Volumn 7, Issue 5, 2005, Pages 323-329

  Taler, Sandra J ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPHEDRA SINICA EXTRACT; ERYTHROPOIETIN; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; ILLICIT DRUG; METADRENALIN; METHYLPHENIDATE; MODAFINIL; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; RENIN; SIBUTRAMINE; SODIUM; TACROLIMUS; UNINDEXED DRUG; VENLAFAXINE;

ACUTE KIDNEY FAILURE; AGING; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; FLUID RETENTION; HIGH RISK POPULATION; HIGH SODIUM INTAKE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; LIFESTYLE; PLASMA RENIN ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; RENOVASCULAR DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; VIRUS PATHOGENESIS; WEIGHT GAIN;

EID: 27544498604     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0064-6     Document Type: Review

References (66)

1. Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002, 287:1003-1010.
2. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (Complete Version). Hypertension 2003, 42:1206-1252.
3. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757-764.
4. Wang J, Staessen JA, Gong L, Liu L: Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000, 160:211-220.
5. Hansson L, Lindholm LH, Ekborn T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
6. ALLHAT: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000, 283:1967-1975.
7. ALLHAT officers: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
8. Estacio R, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
9. Wright JT, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002, 288:2421-2431.
10. Gifford RW Jr: Resistant hypertension: introduction and definitions. Hypertension 1988, 11(Suppl II):II-65-II-66.
11. Psaty BM, Manolio TA, Smith NL, et al.: Time trends in high blood pressure control and the use of antihypertensive medications in older adults: The Cardiovascular Health Study. Arch Intern Med 2002, 162:2325-2332.
12. Alderman MH, Budner N, Cohen H, et al.: Prevalence of drug resistant hypertension. Hypertension 1988, 11(3, Suppl II): II-71-II-75.
13. Swales JD, Bing RF, Heagerty AM, et al.: Treatment of refractory hypertension. Lancet 1982, 1:894-896.
14. Schwenger V, Ritz E: Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Ransplant 1998, 13:3091-3095.
15. Dasgupta I, Madeley RJ, Pringle MAL, et al.: Management of hypertension in patients developing end-stage renal failure. Q J Med 1999, 92:519-525.
16. Brown MA, Buddle ML, Martin A: Is resistant hypertension really resistant? Am J Hyper 2001, 14:1263-1269.
17. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF: Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monitoring 2003, 8:181-185.
18. Pickering TG, Hall JE, Appel LJ, et al.: Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
19. Zachariah PK, Schwartz GL, Sheps SG, et al.: Ambulatory blood pressure for better diagnosis of hypertension: correlation between office and automatic blood pressure recording. Am J Hyper 1988, 1:81A.
20. Canzanello VJ, Jensen PL, Hunder I: Rapid adjustment of antihypertensive drugs produces a durable improvement in blood pressure. Am J Hyper 2001, 14:345-350.
21. Garg JP, Folker AC, Munavvar I, et al.: Resistant hypertension revisited. Am J Hypertension 2002, 15:25A.
22. Yakovlevitch M, Black HR: Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991, 151:1786-1792.
23. Taler SJ, Textor SC, Augustine JE: Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002, 39:982-988.
24. Martell N, Rodriguez-Cerrillo M, Grobbee DE, et al.: High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Pressure 2003, 12:149-154.
25. Logan AG, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19:2271-2277.
26. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, sleep apnea and aldosterone: theory and therapy. Hypertension 2004, 43:518-524.
27. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112-117.
28. Safian RD, TextorSC: Medical progress: renal artery stenosis. N Engl J Med 2001, 344:431-442.
29. Young WF: Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997, 26:801-827.
30. Young WF: Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 1999, 7:207-214.
31. Khosla S, Kunjummen B, Manda R, et al.: Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Catheter Cardiovasc Interv 2003, 58:400-403.
32. Rihal CS, Textor SC, Breen JF, et al.: Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc 2002, 77:309-316.
33. Radermacher J, Chavan A, Bleck J, et al.: Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001, 344:410-417.
34. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
35. Tanabe A, Naruse M, Takagi S, et al.: Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003, 88:2489-2494.
36. Lenders JWM, Pacak K, Walther MM, et al.: Biochemical diagnosis of pheochromocytoma: Which test is best? JAMA 2002, 287:1427-1434.
37. Sawka AM, Jaeschke R, Singh RJ, Young WF: A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003, 88:553-558.
38. Ernst E: The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002, 136:42-53.
39. Shea S, Misra D, Ehrlich MH, et al.: Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Eng J Med 1992, 327:776-781.
40. Nuesch R, Schroeder K, Dieterle T, et al.: Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Br Med J 2001, 323:142-146.
41. Brown MJ, Cruickshank JK, Dominczak AF, et al.: Better blood pressure control: how to combine drugs. J Hum Hypertens 2003, 17:81-86.
42. Laragh JH: Lesson XVI: How to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method and the volume-vasoconstriction analysis. Am J Hypertens 2001, 14:491-503.
43. Laragh JH: Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973, 55:261-274.
44. Deary AJ, Schumann AL, Murfet H, et al.: Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002, 20:771-777.
45. Lip GYH, Beevers M, Beevers DG: The "Birmingham Hypertension Square" for the optimum choice of add-in drugs in the management of resistant hypertension. J Hum Hypertens 1998, 12:761-763.
46. Giles TD, Sander GE: Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies. J Clin Hypertens 2001, 3:346-353.
47. Grim CE: Evolution of diagnostic criteria for primary aldosteronism: Why is it more common in "drug-resistant" hypertension today? Curr Hypertens Rep 2004, 6:485-492.
48. Hood S, Cannon J, Foo R, Brown M: Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005, 5:55-60.
49. Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
50. Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hyper 2003, 16:925-930.
51. Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
52. Finnerty FA Jr, Davidov M, Mroczek WJ, Gavrilovich L: Influence of extracellular fluid volume on response to antihypertensive drugs. Circ Res 1970, XXVI-XXVII(Suppl I):I-71-I-82.
53. Dustan HP, Tarazi RC, Bravo EL: Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Eng J Med 1972, 286:861-866.
54. Ramsay LE, Silas JH, Freestone S: Diuretic treatment of resistant hypertension. Br Med J 1980, 281:1101-1103.
55. Graves JW, Bloomfield RL, Buckalew VM: Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989, 298:361-365.
56. Gustafsson D: Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 1987, 10(Suppl 1):S121-S131.
57. Lund-Johansen P: Hemodynamic effects of antihypertensive agents. in Handbook of Hypertension. Edited by Doyle AE. Amsterdam: Elsevier; 1988:41-72.
58. Johns DW, Peach MJ: Factors that contribute to resistant forms of hypertension: pharmacological considerations. Hypertension 1988, 11(Suppl II):I1-88-II-95.
59. Tarazi RC: The hemodynamics of hypertension. In Hypertension: Physiopathology and Reatment. Edited by Genest J, Kuchel O, Hamet P, Cantin M. New York: McGraw-Hill; 1983: 15-42.
60. Franciosa JA: Application of noninvasive techniques for measuring cardiac output in hypertensive patients. Am Heart J 1988, 116:650-656.
61. Messerli FH, DeCarvalho JGR, Christie B, Frohlich ED: Systemic and regional hemodynamics in low, normal and high cardiac output borderline hypertension. Circulation 1978, 3:441-448.
62. De Maria AN, Raisinghani A: Comparative overview of cardiac output measurement methods: Has impedance cardiography come of age? Congest Heart Fail 2000, 6:60-73.
63. Van De Water JM, Miller TW, Vogel RL, et al.: Impedance cardiography: the next vital sign technology? Chest 2003, 123:2028-2033.
64. Greenberg BH, Hermann DD, Pranulis MF, et al.: Reproducibility of impedance cardiography hemodynamic measures in clinically stable heart failure patients. Congest Heart Fail 2000, 6:74-80.
65. Pickett BR, Buell JC: Validity of cardiac output measurement by computer-averaged impedance cardiography, and comparison with simultaneous thermodilution determinations. Am J Cardiol 1992, 69:1354-1358.
66. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003, 289:2560-2572.